Paper Details

  1. Home
  2. Paper Details

Umbralisib: First Approval.

Author: DhillonSohita, KeamSusan J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Umbralisib, a first-in-class dual phosphatidylinositol 3-kinase delta (PI3Kδ) and casein kinase 1 epsilon (CK1ε) inhibitor, has been approved by the FDA for the treatment of adults with relapsed or refractory marginal zone lymphoma (MZL) and follicular lymphoma (FL). Clinical studies are underway in multiple countries for other haematological malignancies.
Paper Details　
Original Abstract of the Article :
Umbralisib (UKONIQ™) is an oral, first-in-class dual phosphatidylinositol 3-kinase delta (PI3Kδ) and casein kinase 1 epsilon (CK1ε) inhibitor being developed by TG Therapeutics for the treatment of various haematological malignancies. In February 2021, umbralisib received its first approval in the U...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s40265-021-01504-2

データ提供：米国国立医学図書館（NLM）

Umbralisib: A New Hope for Relapsed or Refractory Lymphoma

Lymphoma, a type of cancer that affects the lymphatic system, can be challenging to treat, especially in cases of relapse or resistance to standard therapies. This study highlights the development and approval of umbralisib, a novel dual PI3Kδ and CK1ε inhibitor, for the treatment of relapsed or refractory marginal zone lymphoma (MZL) and follicular lymphoma (FL). It's like discovering a new oasis in the desert of lymphoma treatment, offering a promising new approach for patients who have exhausted other options.

A New Weapon: Targeting PI3Kδ and CK1ε for Lymphoma Treatment

Umbralisib represents a significant advancement in lymphoma treatment, targeting key signaling pathways that play a critical role in lymphoma cell growth and survival. The researchers highlight the clinical trials that have demonstrated the effectiveness of umbralisib in patients with relapsed or refractory MZL and FL, offering hope for those who have previously faced limited treatment options.

A New Era in Lymphoma Treatment: Hope for the Future

The approval of umbralisib represents a significant milestone in lymphoma treatment, offering new hope for patients who have previously faced limited options. It's a reminder that the desert of cancer research is vast and constantly evolving, with new discoveries and therapies emerging to improve patient outcomes.

Dr.Camel's Conclusion

This research highlights the potential of umbralisib as a game-changer in lymphoma treatment, offering a new path for patients who have previously encountered dead ends. It's a reminder that the desert of medicine is constantly evolving, with new discoveries and innovations emerging to provide hope and healing.

Date :
  1. Date Completed 2021-11-15
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

33797740

DOI: Digital Object Identifier

10.1007/s40265-021-01504-2

Related Literature

Article Analysis
・Effects of umbralisib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.